Abstract
Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Current Pharmaceutical Design
Title:QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Volume: 20 Issue: 27
Author(s): Filomena Martins, Cristina Ventura, Susana Santos and Miguel Viveiros
Affiliation:
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Abstract: Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Export Options
About this article
Cite this article as:
Martins Filomena, Ventura Cristina, Santos Susana and Viveiros Miguel, QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164434
DOI https://dx.doi.org/10.2174/1381612819666131118164434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Nitrofurans as Novel Anti-tuberculosis Agents: Identification, Development and Evaluation
Current Topics in Medicinal Chemistry More Good News About Polymeric Plant- and Algae-Derived Biomaterials in Drug Delivery Systems
Current Drug Targets Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies
Current Cancer Drug Targets Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design HIV-Tuberculous Meningitis Co-Infection: A Systematic Review and Meta-Analysis
Current Pharmaceutical Biotechnology Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Current Pharmaceutical Design Drugs Against Mycobacterium tuberculosis 3-Isopropylmalate Dehydrogenase Can be Developed Using Homologous Enzymes as Surrogate Targets
Protein & Peptide Letters IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Why Do We Need New Drug Classes for HIV Treatment and Prevention?
Current Topics in Medicinal Chemistry Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modeling Anti-Allergic Natural Compounds by Molecular Topology
Combinatorial Chemistry & High Throughput Screening Cycloserine Induced Suicidal Tendencies and Kanamycin Induced Ototoxicity in Indian MDR-TB Patient: A Case Report
Current Drug Safety Bacterial β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) as a Target for Novel Antibacterial Agents Design
Current Medicinal Chemistry Particulate Systems as Adjuvants and Carriers for Peptide and Protein Antigens
Current Drug Delivery Explicit Treatment of Water Molecules in Protein-Ligand Docking
Current Computer-Aided Drug Design Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Synthesis and Evaluation of N-Aryl 2-Aminothiazole-4-Carboxamide Derivatives for Activity Against TB
Letters in Drug Design & Discovery